Two studies conducted by Epi-Phare, a joint organization of Medicines and Health Products Safety (ANSM) and Cnam, have assessed the effectiveness of vaccines in preventing severe forms of COVID-19: in people aged 50-74 years and in people aged 75 years and over.
Published on 11 October 2021, these two studies were carried out over a period from 27 December 2020 (when vaccination started in France) to 20 July 2021. They are part of the enhanced vaccine surveillance system set up by the ANSM to identify possible adverse effects of vaccines on French territory that were not observed during clinical trials.
Using the National Health Data System (NHDS), the study compared data from 11 million vaccinated people aged 50 years and older with 11 million unvaccinated people in the same age group (read more about Vie-publique.fr).
